EP2502985A1 - Method for inducing differentiation of dental pulp cells into odontoblasts - Google Patents
Method for inducing differentiation of dental pulp cells into odontoblasts Download PDFInfo
- Publication number
- EP2502985A1 EP2502985A1 EP10831541A EP10831541A EP2502985A1 EP 2502985 A1 EP2502985 A1 EP 2502985A1 EP 10831541 A EP10831541 A EP 10831541A EP 10831541 A EP10831541 A EP 10831541A EP 2502985 A1 EP2502985 A1 EP 2502985A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pulp
- inducing differentiation
- substance capable
- signaling pathway
- activating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000004069 differentiation Effects 0.000 title claims abstract description 76
- 230000001939 inductive effect Effects 0.000 title claims abstract description 58
- 210000004416 odontoblast Anatomy 0.000 title claims abstract description 58
- 238000000034 method Methods 0.000 title claims abstract description 35
- 210000001968 dental pulp cell Anatomy 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims abstract description 76
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims abstract description 53
- 239000000126 substance Substances 0.000 claims abstract description 49
- 230000004156 Wnt signaling pathway Effects 0.000 claims abstract description 48
- 230000003213 activating effect Effects 0.000 claims abstract description 39
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 24
- BAZAXWOYCMUHIX-UHFFFAOYSA-M sodium perchlorate Chemical compound [Na+].[O-]Cl(=O)(=O)=O BAZAXWOYCMUHIX-UHFFFAOYSA-M 0.000 claims abstract description 24
- 229910001488 sodium perchlorate Inorganic materials 0.000 claims abstract description 24
- 102100025036 Norrin Human genes 0.000 claims abstract description 15
- 101710085992 Norrin Proteins 0.000 claims abstract description 15
- 239000000463 material Substances 0.000 claims description 37
- 102000013814 Wnt Human genes 0.000 claims description 31
- 108050003627 Wnt Proteins 0.000 claims description 31
- 229920002971 Heparan sulfate Polymers 0.000 claims description 23
- BZSXEZOLBIJVQK-UHFFFAOYSA-N 2-methylsulfonylbenzoic acid Chemical compound CS(=O)(=O)C1=CC=CC=C1C(O)=O BZSXEZOLBIJVQK-UHFFFAOYSA-N 0.000 claims description 20
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 claims description 19
- 108090000054 Syndecan-2 Proteins 0.000 claims description 19
- 108091016585 CD44 antigen Proteins 0.000 claims description 18
- 239000004480 active ingredient Substances 0.000 claims description 10
- 230000003993 interaction Effects 0.000 claims description 7
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 7
- 108010067306 Fibronectins Proteins 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 102100037362 Fibronectin Human genes 0.000 claims 1
- 210000004268 dentin Anatomy 0.000 description 33
- 101150106419 Dspp gene Proteins 0.000 description 28
- 210000001519 tissue Anatomy 0.000 description 26
- 230000009471 action Effects 0.000 description 14
- 210000002469 basement membrane Anatomy 0.000 description 14
- 208000002925 dental caries Diseases 0.000 description 12
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 8
- 239000000920 calcium hydroxide Substances 0.000 description 8
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 8
- 230000013860 dentinogenesis Effects 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000001172 regenerating effect Effects 0.000 description 7
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 6
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 6
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 6
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 6
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 229940112869 bone morphogenetic protein Drugs 0.000 description 6
- 210000004748 cultured cell Anatomy 0.000 description 6
- 210000000981 epithelium Anatomy 0.000 description 6
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 102100029792 Dentin sialophosphoprotein Human genes 0.000 description 5
- 102000016359 Fibronectins Human genes 0.000 description 5
- 108010088492 dentin sialophosphoprotein Proteins 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 101000865404 Homo sapiens Dentin sialophosphoprotein Proteins 0.000 description 4
- 102000016611 Proteoglycans Human genes 0.000 description 4
- 108010067787 Proteoglycans Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000003827 pulp capping and pulpectomy agent Substances 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 102000015735 Beta-catenin Human genes 0.000 description 3
- 108060000903 Beta-catenin Proteins 0.000 description 3
- 102000006757 Wnt Receptors Human genes 0.000 description 3
- 108010047118 Wnt Receptors Proteins 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 238000009412 basement excavation Methods 0.000 description 3
- 230000033558 biomineral tissue development Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000003298 dental enamel Anatomy 0.000 description 3
- 210000002992 dental papilla Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000003325 follicular Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000032724 odontogenesis Effects 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000000246 tooth germ Anatomy 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102400001058 Dentin phosphoprotein Human genes 0.000 description 2
- 102400001059 Dentin sialoprotein Human genes 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Chemical group O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 2
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- 102000003923 Protein Kinase C Human genes 0.000 description 2
- 108090000315 Protein Kinase C Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003239 periodontal effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- WHRZCXAVMTUTDD-UHFFFAOYSA-N 1h-furo[2,3-d]pyrimidin-2-one Chemical compound N1C(=O)N=C2OC=CC2=C1 WHRZCXAVMTUTDD-UHFFFAOYSA-N 0.000 description 1
- 101150079978 AGRN gene Proteins 0.000 description 1
- 102100040026 Agrin Human genes 0.000 description 1
- 108700019743 Agrin Proteins 0.000 description 1
- 102100036597 Basement membrane-specific heparan sulfate proteoglycan core protein Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000004657 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Human genes 0.000 description 1
- 108010003721 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101000944251 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) Calcium/calmodulin-dependent protein kinase cmkA Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000005698 Frizzled receptors Human genes 0.000 description 1
- 108010045438 Frizzled receptors Proteins 0.000 description 1
- 102000010956 Glypican Human genes 0.000 description 1
- 108050001154 Glypican Proteins 0.000 description 1
- 102000003693 Hedgehog Proteins Human genes 0.000 description 1
- 108090000031 Hedgehog Proteins Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 235000006173 Larrea tridentata Nutrition 0.000 description 1
- 244000073231 Larrea tridentata Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101000713902 Mus musculus Activated RNA polymerase II transcriptional coactivator p15 Proteins 0.000 description 1
- 101000869696 Mus musculus Protein S100-A9 Proteins 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 101150048283 SULF1 gene Proteins 0.000 description 1
- 102000019361 Syndecan Human genes 0.000 description 1
- 108050006774 Syndecan Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 101150109862 WNT-5A gene Proteins 0.000 description 1
- 230000031712 Wnt receptor signaling pathway, planar cell polarity pathway Effects 0.000 description 1
- 102000043366 Wnt-5a Human genes 0.000 description 1
- 108700020483 Wnt-5a Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical group O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 210000001053 ameloblast Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000005204 bell stage Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000003918 blood extract Substances 0.000 description 1
- 230000005200 bud stage Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 230000005203 cap stage Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000033026 cell fate determination Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 210000000250 cementoblast Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229960002126 creosote Drugs 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000005548 dental material Substances 0.000 description 1
- 210000004262 dental pulp cavity Anatomy 0.000 description 1
- 210000002986 dental sac Anatomy 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000001080 enamel organ Anatomy 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- IAJILQKETJEXLJ-LECHCGJUSA-N iduronic acid Chemical group O=C[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-LECHCGJUSA-N 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 230000007154 intracellular accumulation Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 229940124561 microbicide Drugs 0.000 description 1
- 239000002855 microbicide agent Substances 0.000 description 1
- DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000933 neural crest Anatomy 0.000 description 1
- 210000001982 neural crest cell Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
- 210000004261 periodontium Anatomy 0.000 description 1
- 108010049224 perlecan Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000008189 vertebrate development Effects 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- YBTQRZBBLJRNOC-UHFFFAOYSA-N zinc;2-methoxy-4-prop-2-enylphenol;oxygen(2-) Chemical compound [O-2].[Zn+2].COC1=CC(CC=C)=CC=C1O YBTQRZBBLJRNOC-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0654—Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1305—Adipocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1311—Osteocytes, osteoblasts, odontoblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1317—Chondrocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1323—Adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1329—Cardiomyocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1335—Skeletal muscle cells, myocytes, myoblasts, myotubes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1341—Tenocytes, cells from tendons and ligaments
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1347—Smooth muscle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1352—Mesenchymal stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1352—Mesenchymal stem cells
- C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1352—Mesenchymal stem cells
- C12N2502/1364—Dental pulp stem cells, dental follicle stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1352—Mesenchymal stem cells
- C12N2502/137—Blood-borne mesenchymal stem cells, e.g. Msc from umbilical cord blood
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1352—Mesenchymal stem cells
- C12N2502/1376—Mesenchymal stem cells from hair follicles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1352—Mesenchymal stem cells
- C12N2502/1382—Adipose-derived stem cells [ADSC], adipose stromal stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1352—Mesenchymal stem cells
- C12N2502/1388—Mesenchymal stem cells from other natural sources
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1394—Bone marrow stromal cells; whole marrow
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0664—Dental pulp stem cells, Dental follicle stem cells
Definitions
- the present invention relates to a field of regenerative medicine of dentin. Specifically, the present invention relates to a method of inducing differentiation of pulp cells into odontoblasts in a site-specific manner. The present invention also relates to an agent for inducing differentiation of pulp cells into odontoblasts. The present invention also relates to a pulp capping material including as an active ingredient the agent for inducing differentiation.
- Pulp is a vascular connective tissue that fills a cavity called a pulp cavity present inside a tooth, and is a non-mineralized tissue formed from dental papilla derived from mesoderm.
- dentin is a hard mineralized tissue present around the pulp cavity. Based on the structural features that pulp is a soft tissue and dentin is a hard tissue, both the tissues have conventionally been regarded as quite different tissues. However, in recent years, there has been a growing trend that pulp and dentin are regarded as embryologically and functionally homologous tissues, and in clinical situations as well, as a dentin-pulp complex.
- an indirect pulp capping material or a direct pulp capping material is used depending on a damaged condition of dentin and a pathological condition of pulp.
- the indirect pulp capping material is used in such a condition that dentin is damaged but pulp is not exposed, and the direct pulp capping material is used in a case where pulp is exposed or a case where pulp is partially amputated by a treatment.
- a calcium hydroxide formulation and a formocresol formulation have conventionally been used.
- Calcium hydroxide stimulates odontoblasts in pulp in about three months to promote production of second dentin in a pulp cavity. As a result, healthydentin is formedbetween softeneddentin and pulp. After that, the softened dentin is removed.
- calcium hydroxide does not have any action of promoting proliferation of pulp cells and any action of inducing odontoblasts. Hence, a necrosis layer due to a strong alkali is generated in a pulpal surface brought into contact with calcium hydroxide. Further, this method involves causing degeneration and necrosis of a pulpal tissue and regenerating dentin through the subsequent restoration mechanism, and hence involves problems such as a long time required for the method, poor efficiency, and indefinite prognosis.
- Dentin is a hard tissue that accounts for a large share of a tooth and is present in a state in which it supports the inner pulp and the surrounding enamel and cementum. Dentin is formed by mineralization of organic substrates synthesized and secreted from odontoblasts. Most of the organic substrates are collagens, and the remainder (about 10%) is noncollagenous proteins (NCPs). It is known that dentin sialophosphoprotein (Dspp, hereinafter, simply referred to as "Dspp”), which is the most common among the NCPs, is synthesized by odontoblasts, and then the protein produces dentin sialoprotein (DSP), dentin glycoprotein (DGP), and dentin phosphoprotein (DPP).
- DSP dentin sialoprotein
- DGP dentin glycoprotein
- DPP dentin phosphoprotein
- Patent Literature 3 a pulp capping agent (material) for dentinogenesis including a BMP as an active ingredient.
- a bone inducing factor such as a BMP was attempted to be applied to production of dentin, focusing on the fact that a component of a mineralization substrate forming dentin is very similar to that of bone.
- the factor such as a BMP has an effect of promoting production of a mineralization substrate by already differentiated odontoblasts, but does not promote differentiation of pulp cells into odontoblasts.
- the factor has a very limited effect of inducing odontoblasts in an affected tissue.
- Non Patent Literature 1 A method involving regenerating natural dentin and using the natural dentin for a treatment has been proposed and studied. For example, there is a report that a sample obtained by seeding cultured human pulp cells into a hydroxyapatite-tricalcium phosphate complex powder was transplanted subcutaneously into nude mice, extirpation was carried out after 6 weeks, and formation of a hard tissue was confirmed from a hematoxylin/eosin staining image after the extirpation (Non Patent Literature 1).
- pulp capping agent (material) for dentin regeneration including a collagen-fixed ethylene-vinyl acetate copolymer saponification product (A) and a binder (B) (Patent Literature 4).
- pulp capping agent (material) for dentin regeneration has an excellent function of securing a scaffold for proliferation of cells each having an ability to regenerate dentin.
- a method of regenerating dentin there is a disclosure of a method of regenerating dentin involving culturing human pulp cells in the presence of 1, 25 (dihydroxy) vitamin D 3 , dexamethasone, and ⁇ -glycerophosphate to achieve differentiation into odontoblasts, and culturing and/or transplanting the cells together with a carrier or the like (Patent Literatures 5 and 6). Further, as another method, there is a disclosure of a pulp capping agent (material) for dentinogenesis using polyphosphoric acid (Patent Literature 7). However, any of the literatures merely discloses a technology for regenerating dentin from odontoblasts, and none of the literatures discloses induction of differentiation of pulp cells into odontoblasts.
- tooth development proceeds through a close interaction between an odontogenic epithelium and an odontogenic mesenchymal tissue.
- Neural crest-derived mesenchymal cells receive a signal from an ectodermal epithelium tissue and are differentiated into pulp cells.
- Various growth factors are supposed to be involved in this process.
- signals involved in tooth development for example, there are known a BMP, a fibroblast growth factor (FGF), a Wnt, and a sonic hedgehog (Shh).
- FGF fibroblast growth factor
- Wnt fibroblast growth factor
- shh sonic hedgehog
- Non Patent Literature 2 A basement membrane is present between an epithelium and a mesenchymal tissue, and one of the constituents for the basement membrane is a proteoglycan.
- Non Patent Literature 3 There is a report that the Wnt induces secretion of Dspp in neural crest cells at the development stage (Non Patent Literature 3). That is, Non Patent Literature 3 reports the Wnt at the tooth development stage, but does not report that the Wnt is involved in differentiation of pulp cells into odontoblasts and regeneration in the already formed tooth.
- a Wnt signal is conserved across biological species and controls body axis formation and organ formation during early development and cell proliferation and differentiation. It is known that a Wnt signaling pathway includes at least the following three kinds of pathways: 1) a ⁇ -catenin pathway, which regulates a transcription factor via intracellular accumulation of ⁇ -catenin; 2) a PCP pathway, which controls planar cell polarity via the family of Rho as a low molecular weight G protein; and 3) a Ca 2+ pathway, which causes intracellular Ca 2+ recruitment via a trimer G protein to activate protein kinase C (PKC), Ca 2+ /calmodulin-dependent protein kinase II (CaMK II), and the like (Non Patent Literature 5).
- PKC protein kinase C
- CaMK II Ca 2+ /calmodulin-dependent protein kinase II
- An object of the present invention is to provide an efficient method of inducing differentiation of a pulp cell into an odontoblast.
- Another obj ect of the present invention is to provide an agent for inducing differentiation capable of inducing differentiation into an odontoblast efficiently.
- the inventors of the present invention have focused on the involvement of a Wnt signal in the differentiation into an odontoblast and have made extensive studies.
- the inventors have found for the first time that, when a pulp cell is cultured using a substance capable of activating a Wnt signaling pathway, specifically any one selected from sodium chlorate, sodium perchlorate, lithium chloride, Norrin, and R-Spondin2, Dspp as an extracellular matrix specific for an odontoblast is produced in the cultured pulp cell.
- a substance capable of activating a Wnt signaling pathway specifically any one selected from sodium chlorate, sodium perchlorate, lithium chloride, Norrin, and R-Spondin2
- Dspp as an extracellular matrix specific for an odontoblast is produced in the cultured pulp cell.
- the present invention includes the following.
- the use of the substance capable of activating a Wnt signaling pathway significantly enhances the expression of Dspp as an extracellular matrix specific for an odontoblast in a pulp-derived cell line.
- the substance capable of activating a Wnt signaling pathway specifically any one selected from sodium chlorate, sodium perchlorate, lithium chloride, Norrin, and R-Spondin2 is capable of serving as the agent for inducing differentiation of a pulp cell into an odontoblast.
- the pulp capping material including as an active ingredient the agent for inducing differentiation of the present invention has actions of inducing differentiation of a pulp cell into an odontoblast and promoting the subsequent dentinogenesis as well as an action of protecting an exposed pulpal surface.
- the present invention relates to a method of inducing differentiation of a pulp cell into an odontoblast, including using a substance capable of activating a Wnt signaling pathway.
- the inventors of the present invention have confirmed that the induction of Dspp occurs only when Wnt10a-expressing cells are cultured on a Matrigel made from basement membrane extracts, and have found that regulation by both of a Wnt signal and a certain component included in the basement membrane is essential for the differentiation into odontoblasts. Based on this finding, the inventors of the present invention have observed tooth phenotypes of Sulf1/Sulf2 (endosulfatases) double knockout mice. As a result, the inventors have confirmed that dentinogenesis is significantly suppressed in the double knockout mice as compared to wild-type ones.
- the inventors of the present invention have confirmed for the first time an action of inducing differentiation into odontoblasts by allowing the substance capable of activating a Wnt signaling pathway to act on a pulp-derived cell line.
- Dspp which is the most common as a noncollagenous protein among organic substrates synthesized and secreted from odontoblasts, is produced in the pulp derived cell line on which the substance capable of activating a Wnt signaling pathway has been allowed to act.
- the substance capable of activating a Wnt signaling pathway may be a substance capable of directly activating a Wnt signaling pathway or may be a substance capable of indirectly activating a Wnt signaling pathway.
- the substance capable of directly activating a Wnt signaling pathway include any one selected from lithium chloride, Norrin, and R-Spondin2, and examples of the substance capable of indirectly activating a Wnt signaling pathway include sodium chlorate, sodium perchlorate, and endosulfatases.
- the substance capable of directly activating a Wnt signaling pathway refers to a substance that directly acts on a substance acting in a canonical Wnt signaling pathway to activate the Wnt signaling pathway.
- the canonical Wnt signaling pathway specifically a Wnt/ ⁇ -catenin pathway, regulates cell fate determination in the development of vertebrates and invertebrates.
- a Wnt ligand is a secreted glycoprotein that binds to Frizzled receptors, which triggers a signal cascade, resulting in the dissociation of a multifunctional kinase GSK-3 ⁇ from an APC/Axin/GSK-3 ⁇ complex.
- GSK-3 has a suppressive role in the Wnt signaling pathway ( Cell Research, 15 (1) :28-32 (2005 )). It is said that lithium chloride has an action of suppressing GSK-3 ( J Biol Chem., 275(21):15765-72 (2000 )).
- specific examples of the substance capable of directly activating a Wnt signaling pathway include lithium chloride.
- GSK-3 has a suppressive role in the Wnt signaling pathway.
- the addition of lithium chloride is capable of activating the Wnt signaling pathway.
- any of Norrin and R-Spondin2 is a protein capable of directly activating a Wnt signaling pathway.
- examples of the substance capable of indirectly activating a Wnt signaling pathway include a substance capable of regulating an interaction between a heparan sulfate proteoglycan and a Wnt.
- a sugar chain of a proteoglycan in the basement membrane plays an important role in Wnt signaling.
- the Wnt is bound to a sugar chain of the heparan sulfate proteoglycan very strongly.
- examples of the substance capable of regulating an interaction between a heparan sulfate proteoglycan and a Wnt include a substance capable of reducing the affinity of a heparan sulfate proteoglycans to a Wnt.
- Such substance examples include a substance capable of removing a sulfate group from a heparan sulfate proteoglycan.
- a substance capable of removing a sulfate group from a heparan sulfate proteoglycan include sodium chlorate, sodium perchlorate, and endosulfatases. Of those, sodium chlorate and sodium perchlorate are preferred.
- Sodium chlorate has an action capable of removing a sulfate group from a heparan sulfate proteoglycan ( J Biol Chem., 263(26):12886-92 (1988 )).
- the removal of a sulfate group from a heparan sulfate proteoglycan reduces the affinity of a sugar chain to a Wnt.
- the Wnt which has been bound to the heparan sulfate proteoglycan, is dissociated therefrom and transferred to a Wn
- the Wnt is one of the intercellular signal molecules. It is known that the Wnt family includes 17 or more members at present. Wnt10a is found to be expressed in the basement membrane. Among Wnt molecules other than Wnt10a, Wnt5a and Wnt10b are found to be expressed in ameloblasts and cementoblasts.
- the kind of the Wnt to be activated in the Wnt signaling pathway is not particularly limited. However, it is particularly suitable to activate a pathway including Wnt10a in order to induce the differentiation of pulp cells into odontoblasts.
- a tooth is formed from a tooth germ, grows through processes of the bud stage, the cap stage, and the bell stage, and erupts in the mouth.
- the tooth germ is the primordium of the tooth and periodontal tissues and is derived from an ectodermal mesenchymal tissue. Further, the tooth germ is divided into three tissues, i.e., enamel organ, dental papilla, and dental follicle.
- the tooth is structured of three major hard tissues, i.e., enamel, dentin, and cementum. Pulp is present in the interior of these hard tissues (pulp cavity) and dentin is present outside the pulp. The pulp is of the same origin as dental follicular cells.
- the dental follicular cells are mesenchymal tissues derived from dental papilla observed at the development stage. It is said that the dental follicular cells are differentiated into periodontal tissue cells such as periodontium, cementum, and alveolar bone. Odontoblasts are present in the outermost layer of the pulp, and the differentiation into odontoblasts occurs only in the boundary between the epithelium and the mesenchymal tissue.
- the basement membrane In the epithelium of all tissues and organs, there is a unique extracellular matrix (ECM) called the basement membrane lining the epithelium.
- the basement membrane is present between an epithelial cell layer such as enamel and an interstitial cell layer (pulp cell layer) or the like.
- constituent substances for the basement membrane for example, there are given type IV collagen, laminin, and a heparan sulfate proteoglycan.
- the heparan sulfate proteoglycan is present in a state in which a heparan sulfate is added to a protein to serve as a core called a core protein, such as a proteoglycan such as perlecan, syndecan, glypican, or agrin.
- the heparan sulfate has a repetitive structure of disaccharide units of N-acetylglucosamine and glucuronic acid or iduronic acid and exhibits diversity depending on the number of sulfate groups on a sugar chain.
- the heparan sulfate proteoglycan is a collective term for glucosaminoglucans each having added thereto such heparan sulfate and is not particularly limited.
- the present invention also encompasses an agent for inducing differentiation of pulp cells into odontoblasts, including a substance capable of activating a Wnt signaling pathway.
- a substance capable of activating a Wnt signaling pathway include sodium chlorate, sodium perchlorate, lithium chloride, endosulfatases, Norrin, and R-Spondin2. Of those, sodium chlorate, sodium perchlorate, or lithium chloride is preferred.
- the present invention also encompasses a pulp capping material including as an active ingredient the above-mentioned agent for inducing differentiation.
- the pulp capping material of the present invention has actions of inducing differentiation of pulp cells into odontoblasts and promoting dentinogenesis as well as an action of protecting an exposed pulpal surface.
- the pulp capping material of the present invention may be used by being applied onto or filled into the amputated pulpal surface of a cavity after a general treatment for caries such as opening of pulp chamber or extirpation of pulp.
- the pulp capping material of the present invention may be used in combination with a direct pulp capping material or an indirect pulp capping material.
- the pulp capping material of the present invention may be applied before or after the application of the direct pulp capping material or the indirect pulp capping material, or may be applied by being mixed with the direct pulp capping material or the indirect pulp capping material.
- the "direct pulp capping material” refers to a medicament for protecting a pulpal tissue when pulp is partially exposed, and for example, a calcium hydroxide formulation is used.
- the “indirect pulp capping material” refers to a medicament used for the purposes of blocking of external stimulation, sterilization, and the like when dentin is thin but pulp is not exposed, and for example, a zinc oxide eugenol formulation or a zinc oxide creosote formulation is used.
- the content of the agent for inducing differentiation such as sodium chlorate, sodium perchlorate, or lithium chloride in the pulp capping material of the present invention is not particularly limited.
- the content is suitably 5 to 500 mM, preferably 50 to 100 mM.
- the content is suitably 2 to 200 mM, preferably 5 to 50 mM, more preferably about 50 mM.
- the agent for inducing differentiation such as sodium chlorate, sodiumperchlorate, or lithium chloride in the pulp capping material of the present invention may be used as it is or used as a mixture with a pharmacologically and pharmaceutically acceptable additive to prepare various formulations in forms suitable for being applied to an affected area.
- the formulation forms suitable for the pulp capping material of the present invention include injections, liquids for external use (infusions,liniments), solid preparations (granules, fine subtilaes, powdered medicines, ointments, tablets), and ointments.
- the agent for inducing differentiation of the present invention may include fibronectin (FN), for example.
- an excipient for example, an excipient, a disintegrator or a disintegrating aid, a binder, a lubricant, a coating, a coloring, a diluent, a base, a solvent or a dissolving aid, a tonicity agent, a pH adjuster, a stabilizer, an antiseptic, a preservative, a dispersant, an emulsifier, a gelling agent, a thickener, a tackifier, and a corrigent.
- an excipient for example, an excipient, a disintegrator or a disintegrating aid, a binder, a lubricant, a coating, a coloring, a diluent, a base, a solvent or a dissolving aid, a tonicity agent, a pH adjuster, a stabilizer, an antiseptic, a preservative, a dispersant, an emulsifier, a gelling agent, a
- the gelling agent may be, for example, one that absorbs a tooth exudate to gelate.
- a form formed of a powder and a liquid may be mixed and kneaded before use.
- the pulp capping material of the present invention may further include other active ingredients such as a microbicide, an antibiotic, and an anti-inflammatory agent.
- the pulp capping material of the present invention may be carried by a carrier in order to facilitate the application of an active ingredient of a medicament to an affected area and to allow an active ingredient to be kept in an affected area for a period of time enough to induce differentiation into odontoblasts.
- the pulp capping material of the present invention may be in a form of a dental material in which the agent for inducing differentiation of the present invention such as sodium chlorate, sodium perchlorate, or lithium chloride and an appropriate aid are fixed or impregnated into a structure having a shape such as a monofilament, a film, fiber assembly, a sponge, or a fine particle.
- the dose of the pulp capping material of the present invention is not particularly limited and is appropriately adjusted depending on, for example, the symptom (degree of progression of decayed tooth) and age of a patient and a dosage form.
- Example 1 Induction of differentiation into odontoblasts using sodium chlorate (NaClO 3 )
- MEDP cells as a pulp-derived cell line were cultured in a system including NaClO 3 , and the expression of Dspp in the cultured cells was confirmed. The expression of Dspp was confirmed by PCR.
- the MEDP cells were cultured using a DMEM medium containing 10%v/v fetal bovine serum (FBS). The cells were suspended in the medium so that the number of the cells was 3.7 ⁇ 10 5 cells/ml, and 5 ml of the cell suspension were added to a culture vessel having a diameter of 6 cm and cultured. The culture was carried out using a culture vessel coated with fibronectin (FN) at 37 ⁇ 0.5°C. On day 1 of the culture, NaClO 4 was added so that the final concentration was 50 mM or 100 mM, and the cells were cultured for an additional 7 days.
- FBS fetal bovine serum
- RNA had been extracted from the cultured cells using an RNeasy Mini KitTM (manufactured by QIAGEN)
- reverse transcription was carried out using a PrimeScriptTM Reverse Transcriptase (manufactured by TAKARA) to prepare cDNA, which was used as a sample for PCR.
- the extraction of mRNA and the preparation of cDNA were carried out in accordance with the manufacturer's instructions.
- Primers formed of base sequences set forth in SEQ ID NOS: 1 and 2 of the sequence listing were used as primers for amplification of DSPP, and primers formed of base sequences set forth in SEQ ID NOS: 3 and 4 of the sequence listing were used as primers for amplification of GADPH as a control gene.
- the PCR was carried out using a LightCyclerTM (manufactured by Roche).
- the expression amount of DSPP was confirmed with a relative ratio between an amplification product of DSPP and an amplification product of
- the administration of NaClO 3 inhibits the sulfation of a heparan sulfate proteoglycan and dissociates a Wnt from the the cell membrane or the basement membrane, which can bind to a Wnt receptor.
- the administration of NaClO 3 is capable of indirectly activating a Wnt signaling pathway. It was estimated that the differentiation of undifferentiated pulp cells into odontoblasts was promoted as a result of the foregoing fact ( FIG. 1 ).
- MEDP cells as a pulp-derived cell line were cultured in a system including LiCl, and the expression of Dspp in the cultured cells was confirmed.
- the expression of Dspp was confirmed by PCR.
- a treatment for inducing differentiation was carried out by the same technique as that of Example 1 except that LiCl was used in place of NaClO 3 and LiCl was added so that the final concentration was 5 mM or 50 mM on day 1 of the culture. Then, the expression of Dspp was confirmed.
- MEDP cells as a pulp-derived cell line were cultured in a system including NaClO 4 , and the expression of Dspp in the cultured cells was confirmed. The expression of Dspp was confirmed by PCR.
- a treatment for inducing differentiation was carried out by the same technique as that of Example 1 except that NaClO 4 was used in place of NaClO 3 . Then, the expression of Dspp was confirmed.
- MEDP cells as a pulp-derived cell line are cultured in a system including Norrin, and the expression of Dspp in the cultured cells is confirmed.
- the expression of Dspp is confirmed by PCR.
- a treatment for inducing differentiation is carried out by the same technique as that of Example 1 except that Norrin (R&D Systems, Inc.: catalog No.: 3014-NR) is used in place of NaClO 3 .
- Norrin R&D Systems, Inc.: catalog No.: 3014-NR
- the addition concentration of Norrin is to be considered.
- MEDP cells as a pulp-derived cell line are cultured in a system including R-Spondin2, and the expression of Dspp in the cultured cells is confirmed.
- the expression of Dspp is confirmed by PCR.
- a treatment for inducing differentiation is carried out by the same technique as that of Example 1 except that R-Spondin2 (R&D Systems, Inc. : catalog nNo. : 3266-RS/CF) is used in place of NaClO 3 . Then, the expression of Dspp is confirmed.
- the addition concentration of R-Spondin2 is to be considered.
- the use of the substance capable of activating a Wnt signaling pathway of the present invention significantly enhanced the expression of Dspp as an extracellular matrix specific for odontoblasts in the pulp-derived cell line.
- the substance capable of activating a Wnt signaling pathway is capable of serving as an agent for inducing differentiation of pulp cells into odontoblasts.
- the pulp capping material including as an active ingredient the agent for inducing differentiation of the present invention has actions of inducing differentiation of pulp cells into odontoblasts and promoting dentinogenesis as well as an action of protecting an exposed pulpal surface.
- the agent for inducing differentiation of pulp cells into odontoblasts of the present invention has an effect of promoting the induction of differentiation of pulp cells into odontoblasts throughitsdirectactiononpulp.
- dentin is actively regenerated just below caries by directly applying the agent for inducing differentiation to a caries-affected area or filling a paste including the agent for inducing differentiation into a caries-affected area. After the confirmation of sufficient secondary (reparative) dentin formation, a carious lesion is removed, and a reparative treatment with a resin or a metal is carried out.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Rheumatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medical Informatics (AREA)
- Marine Sciences & Fisheries (AREA)
- Mycology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
- The present invention relates to a field of regenerative medicine of dentin. Specifically, the present invention relates to a method of inducing differentiation of pulp cells into odontoblasts in a site-specific manner. The present invention also relates to an agent for inducing differentiation of pulp cells into odontoblasts. The present invention also relates to a pulp capping material including as an active ingredient the agent for inducing differentiation.
- The present application claims priority from Japanese Patent Application No.
, which is incorporated herein by reference.2009-262378 - Hitherto, in a treatment for caries (decayed tooth), there has been employed a treatment method involving removing caries by excavation and filling a resin or cement into a tooth after caries excavation, thereby achieving artificial restoration. When a carious cavity caused by caries is large, pulp excavation is halted once in a state in which part of softened dentin is left, and calcium hydroxide is used as a pulp capping material.
- Pulp is a vascular connective tissue that fills a cavity called a pulp cavity present inside a tooth, and is a non-mineralized tissue formed from dental papilla derived from mesoderm. On the other hand, dentin is a hard mineralized tissue present around the pulp cavity. Based on the structural features that pulp is a soft tissue and dentin is a hard tissue, both the tissues have conventionally been regarded as quite different tissues. However, in recent years, there has been a growing trend that pulp and dentin are regarded as embryologically and functionally homologous tissues, and in clinical situations as well, as a dentin-pulp complex.
- When a tooth is affected by caries, depending on its degree, there is applied a treatment involving protecting pulp without removing it (direct pulp capping), a treatment involving removing only part of pulp (coronal pulp) and preserving radicular pulp (vital pulpotomy), a treatment involving removing the entire pulp and sealing a cavity with a metal or a resin (pulp extirpation), or the like. However, after pulp removal, there arise problems in that dentin weakens because no nutrient is supplied to a tooth and in that no subjective symptom appears when caries progresses again, resulting in exacerbation of caries, because there is no nerve for transmitting pain. Thus, in recent years, it has been considered that it is preferred to preserve pulp as much as possible in order to keep a tooth in a healthy condition. In order to preserve pulp and keep its function, an indirect pulp capping material or a direct pulp capping material is used depending on a damaged condition of dentin and a pathological condition of pulp. The indirect pulp capping material is used in such a condition that dentin is damaged but pulp is not exposed, and the direct pulp capping material is used in a case where pulp is exposed or a case where pulp is partially amputated by a treatment. As the direct pulp capping material, a calcium hydroxide formulation and a formocresol formulation have conventionally been used. However, calcium hydroxide does not have any action of inducing odontoblasts and hence cannot be expected to promote dentinogenesis. Hitherto, there have been reported, as compounds each having an action of promoting dentinogenesis, a bovine blood extract (Patent Literature 1), polysaccharides such as N-acetyl-glucosamine (Patent Literature 2), a bone morphogenetic protein (BMP), and the like.
- Calcium hydroxide stimulates odontoblasts in pulp in about three months to promote production of second dentin in a pulp cavity. As a result, healthydentin is formedbetween softeneddentin and pulp. After that, the softened dentin is removed. However, in this method, calcium hydroxide does not have any action of promoting proliferation of pulp cells and any action of inducing odontoblasts. Hence, a necrosis layer due to a strong alkali is generated in a pulpal surface brought into contact with calcium hydroxide. Further, this method involves causing degeneration and necrosis of a pulpal tissue and regenerating dentin through the subsequent restoration mechanism, and hence involves problems such as a long time required for the method, poor efficiency, and indefinite prognosis.
- Dentin is a hard tissue that accounts for a large share of a tooth and is present in a state in which it supports the inner pulp and the surrounding enamel and cementum. Dentin is formed by mineralization of organic substrates synthesized and secreted from odontoblasts. Most of the organic substrates are collagens, and the remainder (about 10%) is noncollagenous proteins (NCPs). It is known that dentin sialophosphoprotein (Dspp, hereinafter, simply referred to as "Dspp"), which is the most common among the NCPs, is synthesized by odontoblasts, and then the protein produces dentin sialoprotein (DSP), dentin glycoprotein (DGP), and dentin phosphoprotein (DPP).
- A variety of research has been advanced on a method of inducing differentiation of pulp cells into odontoblasts and a method of regenerating dentin. As an alternative to calcium hydroxide, there is a disclosure of a pulp capping agent (material) for dentinogenesis including a BMP as an active ingredient (Patent Literature 3). Use of a bone inducing factor such as a BMP was attempted to be applied to production of dentin, focusing on the fact that a component of a mineralization substrate forming dentin is very similar to that of bone. However, the factor such as a BMP has an effect of promoting production of a mineralization substrate by already differentiated odontoblasts, but does not promote differentiation of pulp cells into odontoblasts. Hence, the factor has a very limited effect of inducing odontoblasts in an affected tissue.
- A method involving regenerating natural dentin and using the natural dentin for a treatment has been proposed and studied. For example, there is a report that a sample obtained by seeding cultured human pulp cells into a hydroxyapatite-tricalcium phosphate complex powder was transplanted subcutaneously into nude mice, extirpation was carried out after 6 weeks, and formation of a hard tissue was confirmed from a hematoxylin/eosin staining image after the extirpation (Non Patent Literature 1). There is also a report that, when RNA extracted from this sample was evaluated using RT-PCR, mRNA of a differentiation marker for odontoblasts was expressed, in other words, the resultant hard tissue was a dentin-like tissue. In this regard, however, an amount of the formed hard tissue is very small, and a larger amount of dentin needs to be regenerated for clinical applications.
- As other technologies relating to dentin regeneration, there is a disclosure of a pulp capping agent (material) for dentin regeneration including a collagen-fixed ethylene-vinyl acetate copolymer saponification product (A) and a binder (B) (Patent Literature 4). Such pulp capping agent (material) for dentin regeneration has an excellent function of securing a scaffold for proliferation of cells each having an ability to regenerate dentin. In addition, as a method of regenerating dentin, there is a disclosure of a method of regenerating dentin involving culturing human pulp cells in the presence of 1, 25 (dihydroxy) vitamin D3, dexamethasone, and β-glycerophosphate to achieve differentiation into odontoblasts, and culturing and/or transplanting the cells together with a carrier or the like (
Patent Literatures 5 and 6). Further, as another method, there is a disclosure of a pulp capping agent (material) for dentinogenesis using polyphosphoric acid (Patent Literature 7). However, any of the literatures merely discloses a technology for regenerating dentin from odontoblasts, and none of the literatures discloses induction of differentiation of pulp cells into odontoblasts. - It is known that tooth development proceeds through a close interaction between an odontogenic epithelium and an odontogenic mesenchymal tissue. Neural crest-derived mesenchymal cells receive a signal from an ectodermal epithelium tissue and are differentiated into pulp cells. Various growth factors are supposed to be involved in this process. As signals involved in tooth development, for example, there are known a BMP, a fibroblast growth factor (FGF), a Wnt, and a sonic hedgehog (Shh). There is also a report suggesting that transforming growth factor (TGF)-β is involved in differentiation of mature pulp cells into odontoblasts.
- A basement membrane is present between an epithelium and a mesenchymal tissue, and one of the constituents for the basement membrane is a proteoglycan. Recent research has clarified that a sugar chain of the proteoglycan of the basement membrane plays an important role in Wnt signaling (Non Patent Literature 2). There is a report that the Wnt induces secretion of Dspp in neural crest cells at the development stage (Non Patent Literature 3). That is,
Non Patent Literature 3 reports the Wnt at the tooth development stage, but does not report that the Wnt is involved in differentiation of pulp cells into odontoblasts and regeneration in the already formed tooth. - There is a report that, when a mouse p14 lower molar tooth tissue was confirmed by in situ hybridization using a [α-35S]UTP-labeled RNA probe, Wnt10a was found to be expressed in the basement membrane, and Dspp as an extracellular matrix specific for odontoblasts was found to be expressed in the basement membrane as with Wnt10a (Non Patent Literature 4: see
FIG. 1 ). There is also a report that, when Wnt10a was forcibly expressed in undifferentiated mesenchymal cells C310T1/2 and the cells were cultured with a Matrigel (basement membrane extracts), Dspp mRNA was expressed after 10 days (Non Patent Literature 4: seeFIG. 2 ). - A Wnt signal is conserved across biological species and controls body axis formation and organ formation during early development and cell proliferation and differentiation. It is known that a Wnt signaling pathway includes at least the following three kinds of pathways: 1) a β-catenin pathway, which regulates a transcription factor via intracellular accumulation of β-catenin; 2) a PCP pathway, which controls planar cell polarity via the family of Rho as a low molecular weight G protein; and 3) a Ca2+ pathway, which causes intracellular Ca2+ recruitment via a trimer G protein to activate protein kinase C (PKC), Ca2+/calmodulin-dependent protein kinase II (CaMK II), and the like (Non Patent Literature 5). However, a method of inducing differentiation of pulp cells into odontoblasts to form dentin has not been elucidated yet.
-
- [PTL 1]
JP 2002-363084 A - [PTL 2]
JP 06-256132 A - [PTL 3]
JP 06-340555 A - [PTL 4]
JP 2004-292433 A - [PTL 5]
JP 2005-341961 A - [PTL 6]
JP 2006-211957 A - [PTL 7]
JP 2005-263681 A -
- [NPL 1] Proc. Natl. Acad. Sci. USA, 97(25), 13625-30 (2000)
- [NPL 2] J Cell Biol., 162(2), 341-51 (2003)
- [NPL 3] Differentiation, 75(5), 52-62 (2007)
- [NPL 4] European Cells and Materials, Vol. 14, Suppl. 2, 140 (2007)
- [NPL 5] Protein, Nucleic Acid and Enzyme, Vol. 49(10), 1421-1427 (2004)
- An object of the present invention is to provide an efficient method of inducing differentiation of a pulp cell into an odontoblast. Another obj ect of the present invention is to provide an agent for inducing differentiation capable of inducing differentiation into an odontoblast efficiently.
- In order to achieve the above-mentioned objects, the inventors of the present invention have focused on the involvement of a Wnt signal in the differentiation into an odontoblast and have made extensive studies. As a result, the inventors have found for the first time that, when a pulp cell is cultured using a substance capable of activating a Wnt signaling pathway, specifically any one selected from sodium chlorate, sodium perchlorate, lithium chloride, Norrin, and R-Spondin2, Dspp as an extracellular matrix specific for an odontoblast is produced in the cultured pulp cell. Thus, the present invention has been completed.
- That is, the present invention includes the following.
- 1. A method of inducing differentiation of a pulp cell into an odontoblast, including using a substance capable of activating a Wnt signaling pathway.
- 2. A method of inducing differentiation according to the above-mentioned
item 1, in which the substance capable of activating a Wnt signaling pathway includes a substance capable of directly or indirectly activating a Wnt signaling pathway. - 3. A method of inducing differentiation according to the above-mentioned
item 2, in which the substance capable of indirectly activating a Wnt signaling pathway includes a substance capable of regulating an interaction between a heparan sulfate proteoglycan and a Wnt. - 4. A method of inducing differentiation according to the above-mentioned
item 3, in which the substance capable of regulating an interaction between a heparan sulfate proteoglycan and a Wnt includes a substance capable of removing a sulfate group from a heparan sulfate proteoglycan. - 5. A method of inducing differentiation according to any one of the above-mentioned
items 1 to 4, in which the substance capable of activating a Wnt signaling pathway includes any one selected from sodium chlorate, sodium perchlorate, lithium chloride, Norrin, and R-Spondin2. - 6. A method of inducing differentiation according to any one of the above-mentioned
items 1 to 5, in which the Wnt includes Wnt10a. - 7. An agent for inducing differentiation of a pulp cell into an odontoblast, including a substance capable of activating a Wnt signaling pathway.
- 8. An agent for inducing differentiation according to the above-mentioned item 7, in which the substance capable of activating a Wnt signaling pathway includes any one selected from sodium chlorate, sodium perchlorate, lithium chloride, Norrin, and R-Spondin2.
- 9. A pulp capping material, including as an active ingredient the agent for inducing differentiation according to the above-mentioned item 7 or 8.
- 10. A pulp capping material according to the above-mentioned item 9, further including fibronectin.
- The use of the substance capable of activating a Wnt signaling pathway, specifically any one selected from sodium chlorate, sodium perchlorate, lithium chloride, Norrin, and R-Spondin2 significantly enhances the expression of Dspp as an extracellular matrix specific for an odontoblast in a pulp-derived cell line. As a result, the substance capable of activating a Wnt signaling pathway, specifically any one selected from sodium chlorate, sodium perchlorate, lithium chloride, Norrin, and R-Spondin2, is capable of serving as the agent for inducing differentiation of a pulp cell into an odontoblast. In addition, the pulp capping material including as an active ingredient the agent for inducing differentiation of the present invention has actions of inducing differentiation of a pulp cell into an odontoblast and promoting the subsequent dentinogenesis as well as an action of protecting an exposed pulpal surface.
-
- [
FIG. 1 ] A graph showing the expression of Dspp when sodium chlorate is added at different concentrations to MEDP cells as a pulp-derived cell line and the cells are cultured (Example 1). - [
FIG. 2 ] A graph showing the expression of Dspp when lithium chloride is added at different concentrations to MEDP cells as a pulp-derived cell line and the cells are cultured (Example 2). - The present invention relates to a method of inducing differentiation of a pulp cell into an odontoblast, including using a substance capable of activating a Wnt signaling pathway.
- The inventors of the present invention have confirmed that the induction of Dspp occurs only when Wnt10a-expressing cells are cultured on a Matrigel made from basement membrane extracts, and have found that regulation by both of a Wnt signal and a certain component included in the basement membrane is essential for the differentiation into odontoblasts. Based on this finding, the inventors of the present invention have observed tooth phenotypes of Sulf1/Sulf2 (endosulfatases) double knockout mice. As a result, the inventors have confirmed that dentinogenesis is significantly suppressed in the double knockout mice as compared to wild-type ones.
- Based on the above-mentioned findings, the inventors of the present invention have confirmed for the first time an action of inducing differentiation into odontoblasts by allowing the substance capable of activating a Wnt signaling pathway to act on a pulp-derived cell line. As a result, the inventors have found that Dspp, which is the most common as a noncollagenous protein among organic substrates synthesized and secreted from odontoblasts, is produced in the pulp derived cell line on which the substance capable of activating a Wnt signaling pathway has been allowed to act.
- In the present invention, the substance capable of activating a Wnt signaling pathway may be a substance capable of directly activating a Wnt signaling pathway or may be a substance capable of indirectly activating a Wnt signaling pathway. Examples of the substance capable of directly activating a Wnt signaling pathway include any one selected from lithium chloride, Norrin, and R-Spondin2, and examples of the substance capable of indirectly activating a Wnt signaling pathway include sodium chlorate, sodium perchlorate, and endosulfatases.
- Herein, the substance capable of directly activating a Wnt signaling pathway refers to a substance that directly acts on a substance acting in a canonical Wnt signaling pathway to activate the Wnt signaling pathway. The canonical Wnt signaling pathway, specifically a Wnt/β-catenin pathway, regulates cell fate determination in the development of vertebrates and invertebrates. A Wnt ligand is a secreted glycoprotein that binds to Frizzled receptors, which triggers a signal cascade, resulting in the dissociation of a multifunctional kinase GSK-3β from an APC/Axin/GSK-3β complex. In this context, it is known that GSK-3 has a suppressive role in the Wnt signaling pathway (Cell Research, 15 (1) :28-32 (2005)). It is said that lithium chloride has an action of suppressing GSK-3 (J Biol Chem., 275(21):15765-72 (2000)). From the above-mentioned viewpoints, specific examples of the substance capable of directly activating a Wnt signaling pathway include lithium chloride. GSK-3 has a suppressive role in the Wnt signaling pathway. Hence, the addition of lithium chloride is capable of activating the Wnt signaling pathway. It is said that any of Norrin and R-Spondin2 is a protein capable of directly activating a Wnt signaling pathway.
- Herein, examples of the substance capable of indirectly activating a Wnt signaling pathway include a substance capable of regulating an interaction between a heparan sulfate proteoglycan and a Wnt. Recent research has clarified that a sugar chain of a proteoglycan in the basement membrane plays an important role in Wnt signaling. The Wnt is bound to a sugar chain of the heparan sulfate proteoglycan very strongly. However, when a sulfate group is removed from heparan sulfate by an endosulfatase, the affinity of the sugar chain to the Wnt lowers, and the Wnt, which has been bound to the heparan sulfate proteoglycan, is dissociated therefrom and transferred to a Wnt receptor, resulting in the activation of a Wnt signal. In the present invention, examples of the substance capable of regulating an interaction between a heparan sulfate proteoglycan and a Wnt include a substance capable of reducing the affinity of a heparan sulfate proteoglycans to a Wnt. Examples of such substance include a substance capable of removing a sulfate group from a heparan sulfate proteoglycan. Specific examples thereof include sodium chlorate, sodium perchlorate, and endosulfatases. Of those, sodium chlorate and sodium perchlorate are preferred. Sodium chlorate has an action capable of removing a sulfate group from a heparan sulfate proteoglycan (J Biol Chem., 263(26):12886-92 (1988)). The removal of a sulfate group from a heparan sulfate proteoglycan reduces the affinity of a sugar chain to a Wnt. As a result, the Wnt, which has been bound to the heparan sulfate proteoglycan, is dissociated therefrom and transferred to a Wnt receptor, and thus a Wnt signaling pathway is activated.
- The Wnt is one of the intercellular signal molecules. It is known that the Wnt family includes 17 or more members at present. Wnt10a is found to be expressed in the basement membrane. Among Wnt molecules other than Wnt10a, Wnt5a and Wnt10b are found to be expressed in ameloblasts and cementoblasts. In the present invention, the kind of the Wnt to be activated in the Wnt signaling pathway is not particularly limited. However, it is particularly suitable to activate a pathway including Wnt10a in order to induce the differentiation of pulp cells into odontoblasts.
- A tooth is formed from a tooth germ, grows through processes of the bud stage, the cap stage, and the bell stage, and erupts in the mouth. The tooth germ is the primordium of the tooth and periodontal tissues and is derived from an ectodermal mesenchymal tissue. Further, the tooth germ is divided into three tissues, i.e., enamel organ, dental papilla, and dental follicle. The tooth is structured of three major hard tissues, i.e., enamel, dentin, and cementum. Pulp is present in the interior of these hard tissues (pulp cavity) and dentin is present outside the pulp. The pulp is of the same origin as dental follicular cells. In this context, the dental follicular cells are mesenchymal tissues derived from dental papilla observed at the development stage. It is said that the dental follicular cells are differentiated into periodontal tissue cells such as periodontium, cementum, and alveolar bone. Odontoblasts are present in the outermost layer of the pulp, and the differentiation into odontoblasts occurs only in the boundary between the epithelium and the mesenchymal tissue.
- In the epithelium of all tissues and organs, there is a unique extracellular matrix (ECM) called the basement membrane lining the epithelium. The basement membrane is present between an epithelial cell layer such as enamel and an interstitial cell layer (pulp cell layer) or the like. As constituent substances for the basement membrane, for example, there are given type IV collagen, laminin, and a heparan sulfate proteoglycan. The heparan sulfate proteoglycan is present in a state in which a heparan sulfate is added to a protein to serve as a core called a core protein, such as a proteoglycan such as perlecan, syndecan, glypican, or agrin. The heparan sulfate has a repetitive structure of disaccharide units of N-acetylglucosamine and glucuronic acid or iduronic acid and exhibits diversity depending on the number of sulfate groups on a sugar chain. In the present invention, the heparan sulfate proteoglycan is a collective term for glucosaminoglucans each having added thereto such heparan sulfate and is not particularly limited.
- The present invention also encompasses an agent for inducing differentiation of pulp cells into odontoblasts, including a substance capable of activating a Wnt signaling pathway. As described above, specific examples of the substance capable of activating a Wnt signaling pathway include sodium chlorate, sodium perchlorate, lithium chloride, endosulfatases, Norrin, and R-Spondin2. Of those, sodium chlorate, sodium perchlorate, or lithium chloride is preferred.
- The present invention also encompasses a pulp capping material including as an active ingredient the above-mentioned agent for inducing differentiation. The pulp capping material of the present invention has actions of inducing differentiation of pulp cells into odontoblasts and promoting dentinogenesis as well as an action of protecting an exposed pulpal surface. The pulp capping material of the present invention may be used by being applied onto or filled into the amputated pulpal surface of a cavity after a general treatment for caries such as opening of pulp chamber or extirpation of pulp. The pulp capping material of the present invention may be used in combination with a direct pulp capping material or an indirect pulp capping material. The pulp capping material of the present invention may be applied before or after the application of the direct pulp capping material or the indirect pulp capping material, or may be applied by being mixed with the direct pulp capping material or the indirect pulp capping material. Herein, the "direct pulp capping material" refers to a medicament for protecting a pulpal tissue when pulp is partially exposed, and for example, a calcium hydroxide formulation is used. The "indirect pulp capping material" refers to a medicament used for the purposes of blocking of external stimulation, sterilization, and the like when dentin is thin but pulp is not exposed, and for example, a zinc oxide eugenol formulation or a zinc oxide creosote formulation is used.
- The content of the agent for inducing differentiation such as sodium chlorate, sodium perchlorate, or lithium chloride in the pulp capping material of the present invention is not particularly limited. In the case of sodium chlorate or sodium perchlorate, for example, the content is suitably 5 to 500 mM, preferably 50 to 100 mM. Further, in the case of lithium chloride, for example, the content is suitably 2 to 200 mM, preferably 5 to 50 mM, more preferably about 50 mM.
- The agent for inducing differentiation such as sodium chlorate, sodiumperchlorate, or lithium chloride in the pulp capping material of the present invention may be used as it is or used as a mixture with a pharmacologically and pharmaceutically acceptable additive to prepare various formulations in forms suitable for being applied to an affected area. Examples of the formulation forms suitable for the pulp capping material of the present invention include injections, liquids for external use (infusions,liniments), solid preparations (granules, fine subtilaes, powdered medicines, ointments, tablets), and ointments. The agent for inducing differentiation of the present invention may include fibronectin (FN), for example.
- As the pharmacologically and pharmaceutically acceptable additive, there may be used, for example, an excipient, a disintegrator or a disintegrating aid, a binder, a lubricant, a coating, a coloring, a diluent, a base, a solvent or a dissolving aid, a tonicity agent, a pH adjuster, a stabilizer, an antiseptic, a preservative, a dispersant, an emulsifier, a gelling agent, a thickener, a tackifier, and a corrigent.
- The gelling agent may be, for example, one that absorbs a tooth exudate to gelate. Alternatively, a form formed of a powder and a liquid may be mixed and kneaded before use. The pulp capping material of the present invention may further include other active ingredients such as a microbicide, an antibiotic, and an anti-inflammatory agent.
- The pulp capping material of the present invention may be carried by a carrier in order to facilitate the application of an active ingredient of a medicament to an affected area and to allow an active ingredient to be kept in an affected area for a period of time enough to induce differentiation into odontoblasts. Thus, the pulp capping material of the present invention may be in a form of a dental material in which the agent for inducing differentiation of the present invention such as sodium chlorate, sodium perchlorate, or lithium chloride and an appropriate aid are fixed or impregnated into a structure having a shape such as a monofilament, a film, fiber assembly, a sponge, or a fine particle.
- The dose of the pulp capping material of the present invention is not particularly limited and is appropriately adjusted depending on, for example, the symptom (degree of progression of decayed tooth) and age of a patient and a dosage form.
- Hereinafter, the present invention is more specifically described by way of examples. However, the present invention is by no means limited to the scope of the following examples.
- In this example, MEDP cells as a pulp-derived cell line were cultured in a system including NaClO3, and the expression of Dspp in the cultured cells was confirmed. The expression of Dspp was confirmed by PCR.
- The MEDP cells were cultured using a DMEM medium containing 10%v/v fetal bovine serum (FBS). The cells were suspended in the medium so that the number of the cells was 3.7×105 cells/ml, and 5 ml of the cell suspension were added to a culture vessel having a diameter of 6 cm and cultured. The culture was carried out using a culture vessel coated with fibronectin (FN) at 37±0.5°C. On
day 1 of the culture, NaClO4 was added so that the final concentration was 50 mM or 100 mM, and the cells were cultured for an additional 7 days. - After mRNA had been extracted from the cultured cells using an RNeasy Mini Kit™ (manufactured by QIAGEN), reverse transcription was carried out using a PrimeScript™ Reverse Transcriptase (manufactured by TAKARA) to prepare cDNA, which was used as a sample for PCR. The extraction of mRNA and the preparation of cDNA were carried out in accordance with the manufacturer's instructions. Primers formed of base sequences set forth in SEQ ID NOS: 1 and 2 of the sequence listing were used as primers for amplification of DSPP, and primers formed of base sequences set forth in SEQ ID NOS: 3 and 4 of the sequence listing were used as primers for amplification of GADPH as a control gene. The PCR was carried out using a LightCycler™ (manufactured by Roche). The expression amount of DSPP was confirmed with a relative ratio between an amplification product of DSPP and an amplification product of
- A. Primers for amplification of DSPP
- (SEQ NO: 1) forward 5'-AGCCGTGGAGATGCTTCTTA-3'
- (SEQ NO: 2) reverse 5'-TCACTCTGGCTGTCACCATC-3'
B. Primers for amplification of GADPH - (SEQ NO: 3) forward 5'-TGCACCACCAACTGCTTAG-3'
- (SEQ NO: 4) reverse 5'-GGATGCAGGGATGATGTTC-3'
- The results confirmed that, in the culture in the system including NaClO3, the expression of Dspp was significantly enhanced and the differentiation of undifferentiated pulp cells into odontoblasts was induced. The administration of NaClO3 inhibits the sulfation of a heparan sulfate proteoglycan and dissociates a Wnt from the the cell membrane or the basement membrane, which can bind to a Wnt receptor. Thus, the administration of NaClO3 is capable of indirectly activating a Wnt signaling pathway. It was estimated that the differentiation of undifferentiated pulp cells into odontoblasts was promoted as a result of the foregoing fact (
FIG. 1 ). - In this example, MEDP cells as a pulp-derived cell line were cultured in a system including LiCl, and the expression of Dspp in the cultured cells was confirmed. The expression of Dspp was confirmed by PCR.
A treatment for inducing differentiation was carried out by the same technique as that of Example 1 except that LiCl was used in place of NaClO3 and LiCl was added so that the final concentration was 5 mM or 50 mM onday 1 of the culture. Then, the expression of Dspp was confirmed. - The results confirmed that, in the culture of the pulp cells in the system including LiCl, the expression of Dspp was significantly enhanced and the differentiation of undifferentiated pulp cells into odontoblasts was induced. It is said that LiCl has an action of suppressing GSK-3. GSK-3 has a suppressive role in the Wnt signaling pathway, and LiCl is capable of directly activating the Wnt signaling pathway by suppressing GSK-3. It was estimated that the differentiation of undifferentiated pulp cells into odontoblasts was promoted as a result of the foregoing fact (
FIG. 2 ). - In this example, MEDP cells as a pulp-derived cell line were cultured in a system including NaClO4, and the expression of Dspp in the cultured cells was confirmed. The expression of Dspp was confirmed by PCR.
- A treatment for inducing differentiation was carried out by the same technique as that of Example 1 except that NaClO4 was used in place of NaClO3. Then, the expression of Dspp was confirmed.
- In this example, MEDP cells as a pulp-derived cell line are cultured in a system including Norrin, and the expression of Dspp in the cultured cells is confirmed. The expression of Dspp is confirmed by PCR.
A treatment for inducing differentiation is carried out by the same technique as that of Example 1 except that Norrin (R&D Systems, Inc.: catalog No.: 3014-NR) is used in place of NaClO3. Then, the expression of Dspp is confirmed. The addition concentration of Norrin is to be considered. - In this example, MEDP cells as a pulp-derived cell line are cultured in a system including R-Spondin2, and the expression of Dspp in the cultured cells is confirmed. The expression of Dspp is confirmed by PCR.
A treatment for inducing differentiation is carried out by the same technique as that of Example 1 except that R-Spondin2 (R&D Systems, Inc. : catalog nNo. : 3266-RS/CF) is used in place of NaClO3. Then, the expression of Dspp is confirmed. The addition concentration of R-Spondin2 is to be considered. - As described in detail above, it was found that the use of the substance capable of activating a Wnt signaling pathway of the present invention, specifically sodium chlorate, sodium perchlorate, or lithium chloride, significantly enhanced the expression of Dspp as an extracellular matrix specific for odontoblasts in the pulp-derived cell line. As a result, the substance capable of activating a Wnt signaling pathway is capable of serving as an agent for inducing differentiation of pulp cells into odontoblasts. In addition,the pulp capping materialincluding as an active ingredient the agent for inducing differentiation of the present invention has actions of inducing differentiation of pulp cells into odontoblasts and promoting dentinogenesis as well as an action of protecting an exposed pulpal surface.
- The agent for inducing differentiation of pulp cells into odontoblasts of the present invention has an effect of promoting the induction of differentiation of pulp cells into odontoblasts throughitsdirectactiononpulp. Thus, in its clinical applications, it is expected that dentin is actively regenerated just below caries by directly applying the agent for inducing differentiation to a caries-affected area or filling a paste including the agent for inducing differentiation into a caries-affected area. After the confirmation of sufficient secondary (reparative) dentin formation, a carious lesion is removed, and a reparative treatment with a resin or a metal is carried out.
Claims (10)
- A method of inducing differentiation of a pulp cell into an odontoblast, comprising using a substance capable of activating a Wnt signaling pathway.
- A method of inducing differentiation according to claim 1, wherein the substance capable of activating a Wnt signaling pathway comprises a substance capable of directly or indirectly activating a Wnt signaling pathway.
- A method of inducing differentiation according to claim 2, wherein the substance capable of indirectly activating a Wnt signaling pathway comprises a substance capable of regulating an interaction between a heparan sulfate proteoglycan and a Wnt.
- A method of inducing differentiation according to claim 3, wherein the substance capable of regulating an interaction between a heparan sulfate proteoglycan and a Wnt comprises a substance capable of removing a sulfate group from a heparan sulfate proteoglycan.
- A method of inducing differentiation according to any one of claims 1 to 4, wherein the substance capable of activating a Wnt signaling pathway comprises any one selected from sodium chlorate, sodium perchlorate, lithium chloride, Norrin, and R-Spondin2.
- A method of inducing differentiation according to any one of claims 1 to 5, wherein the Wnt comprises Wnt10a.
- An agent for inducing differentiation of a pulp cell into an odontoblast, comprising a substance capable of activating a Wnt signaling pathway.
- An agent for inducing differentiation according to claim 7, wherein the substance capable of activating a Wnt signaling pathway comprises any one selected from sodium chlorate, sodium perchlorate, lithium chloride, Norrin, and R-Spondin2.
- A pulp capping material, comprising as an active ingredient the agent for inducing differentiation according to claim 7 or 8.
- A pulp capping material according to claim 9, further comprising fibronectin.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009262378 | 2009-11-17 | ||
| PCT/JP2010/070330 WO2011062147A1 (en) | 2009-11-17 | 2010-11-16 | Method for inducing differentiation of dental pulp cells into odontoblasts |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EP2502985A1 true EP2502985A1 (en) | 2012-09-26 |
| EP2502985A4 EP2502985A4 (en) | 2013-04-24 |
| EP2502985B1 EP2502985B1 (en) | 2015-04-29 |
Family
ID=44059625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP20100831541 Not-in-force EP2502985B1 (en) | 2009-11-17 | 2010-11-16 | Method for inducing differentiation of dental pulp cells into odontoblasts |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8993000B2 (en) |
| EP (1) | EP2502985B1 (en) |
| JP (1) | JP5808053B2 (en) |
| CN (1) | CN102686720B (en) |
| WO (1) | WO2011062147A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015009261A3 (en) * | 2013-07-16 | 2015-04-16 | Yeditepe Universitesi | Product used in differentiation of human tooth stem cells |
| EP2889373A1 (en) * | 2013-12-25 | 2015-07-01 | Yeditepe Universitesi | Dental differentiation product |
| WO2018073599A1 (en) * | 2016-10-21 | 2018-04-26 | King's College London | Dental treatment |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101524488B1 (en) * | 2013-08-01 | 2015-06-01 | 전남대학교산학협력단 | Dental composition for inducing differentiation of odontoblast |
| WO2016068257A1 (en) * | 2014-10-31 | 2016-05-06 | 国立大学法人東北大学 | Method for producing cell and method for producing blood-forming tissue |
| CA3009983A1 (en) * | 2014-12-29 | 2016-07-07 | The Board Of Trustees Of The Leland Stanford Junior University | Lyposomal wnt3a for use in treating tooth sensitivity |
| WO2020230192A1 (en) * | 2019-05-10 | 2020-11-19 | 日本歯科薬品株式会社 | Dental root canal filling material composition |
| JP2021027803A (en) * | 2019-08-09 | 2021-02-25 | 国立研究開発法人国立長寿医療研究センター | Cell culture for dentin regeneration |
| CN114106094B (en) * | 2021-10-22 | 2023-11-03 | 天津市口腔医院(天津市整形外科医院、南开大学口腔医院) | Polypeptide, polypeptide derivative and nanofiber capable of inducing odontoblast differentiation and mineralization of human dental pulp cells and application of polypeptide and polypeptide derivative and nanofiber |
| JPWO2024070172A1 (en) * | 2022-09-26 | 2024-04-04 | ||
| CN120249196B (en) * | 2025-04-10 | 2026-01-27 | 广州医科大学附属口腔医院(广州医科大学羊城医院) | A method for preparing lithium chloride-induced SHEDs three-dimensional microspheres, an injectable complex and its application. |
| CN120884706B (en) * | 2025-09-29 | 2025-12-30 | 首都医科大学 | Dentin inducer for enhancing succinylation of histone and application thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06256132A (en) | 1993-03-05 | 1994-09-13 | Sunstar Inc | Dental pulp coating agent |
| JPH06340555A (en) | 1993-06-02 | 1994-12-13 | Suntory Ltd | Pulp-capping agent enabling formation of dentine |
| JP2002363084A (en) | 2001-05-31 | 2002-12-18 | Univ Nihon | Second dentin formation promoter |
| AU2003206844B2 (en) * | 2002-02-06 | 2010-04-08 | Tissuedent Gmbh & Co. Kg | Pluripotent embryonic-like stem cells derived from teeth and uses thereof |
| JP4592302B2 (en) | 2003-03-07 | 2010-12-01 | 日本合成化学工業株式会社 | Dentin regenerated pulp capping agent |
| JP4575687B2 (en) | 2004-03-18 | 2010-11-04 | リジェンティス株式会社 | Dentinogenic pulp capping agent |
| JP2005341961A (en) | 2004-05-07 | 2005-12-15 | Hitachi Medical Corp | Method for inducing differentiation of human dental pulp cells and composition for regeneration of dentin |
| US7850960B2 (en) * | 2004-12-30 | 2010-12-14 | University Of Washington | Methods for regulation of stem cells |
| JP4884678B2 (en) | 2005-02-03 | 2012-02-29 | 国立大学法人名古屋大学 | Dentin regeneration from human dental pulp cells |
| CA2609927A1 (en) * | 2005-04-27 | 2006-11-02 | Leiden University Medical Center | Methods and means for the treatment of hpv induced intraepithelial neoplasias |
| EP1981910B1 (en) * | 2006-01-13 | 2013-06-26 | A Chan Holding B.V. | Method for identifying inhibitor of the glypican-sclerostin interaction |
| JP5275223B2 (en) * | 2007-03-30 | 2013-08-28 | 株式会社オーガンテクノロジーズ | Dentin formation promoter and dentin formation pulp capping material |
| JP5572291B2 (en) * | 2008-04-07 | 2014-08-13 | 独立行政法人国立長寿医療研究センター | Drug for promoting formation of dental pulp and / or dentin and use thereof |
| JP2009262378A (en) | 2008-04-23 | 2009-11-12 | Daikin Ind Ltd | Surface material, its manufacturing method, building, outdoor unit casing of air-conditioner, and outdoor heat exchanger |
| KR101198918B1 (en) * | 2009-09-01 | 2012-11-07 | (주)케어젠 | WNT10 Derived Peptides and Uses Thereof |
| CN103403148A (en) * | 2010-10-01 | 2013-11-20 | 纽约市哥伦比亚大学理事会 | Production of dentin, cementum and enamel by cells |
| JP6185463B2 (en) * | 2011-07-15 | 2017-08-23 | オンコメッド ファーマシューティカルズ インコーポレイテッド | RSPO binder and method of use thereof |
-
2010
- 2010-11-16 CN CN2010800518716A patent/CN102686720B/en active Active
- 2010-11-16 WO PCT/JP2010/070330 patent/WO2011062147A1/en not_active Ceased
- 2010-11-16 JP JP2011541917A patent/JP5808053B2/en active Active
- 2010-11-16 EP EP20100831541 patent/EP2502985B1/en not_active Not-in-force
- 2010-11-16 US US13/510,535 patent/US8993000B2/en active Active
Non-Patent Citations (5)
| Title |
|---|
| R. N. D'SOUZA ET AL: "Gene Expression Patterns of Murine Dentin Matrix Protein 1 (Dmp1) and Dentin Sialophosphoprotein (DSPP) Suggest Distinct Developmental Functions In Vivo", JOURNAL OF BONE AND MINERAL RESEARCH, vol. 12, no. 12, 1 December 1997 (1997-12-01), pages 2040-2049, XP055056990, ISSN: 0884-0431, DOI: 10.1359/jbmr.1997.12.12.2040 * |
| See also references of WO2011062147A1 * |
| SHANGXI XIAO ET AL: NATURE GENETICS, vol. 27, no. 2, 1 February 2001 (2001-02-01), pages 201-204, XP055056994, ISSN: 1061-4036, DOI: 10.1038/84848 * |
| SHORTKROFF ET AL: "Alteration of matrix glycosaminoglycans diminishes articular chondrocytes' response to a canonical Wnt signal", OSTEOARTHRITIS AND CARTILAGE, BAILLIERE TINDALL, LONDON, GB, vol. 15, no. 2, 26 January 2007 (2007-01-26), pages 147-154, XP005853747, ISSN: 1063-4584, DOI: 10.1016/J.JOCA.2006.07.004 * |
| X. AI ET AL: "QSulf1 remodels the 6-O sulfation states of cell surface heparan sulfate proteoglycans to promote Wnt signaling", THE JOURNAL OF CELL BIOLOGY, vol. 162, no. 2, 1 July 2003 (2003-07-01), pages 341-351, XP055056986, ISSN: 0021-9525, DOI: 10.1083/jcb.200212083 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015009261A3 (en) * | 2013-07-16 | 2015-04-16 | Yeditepe Universitesi | Product used in differentiation of human tooth stem cells |
| EP2889373A1 (en) * | 2013-12-25 | 2015-07-01 | Yeditepe Universitesi | Dental differentiation product |
| WO2018073599A1 (en) * | 2016-10-21 | 2018-04-26 | King's College London | Dental treatment |
| CN110114048A (en) * | 2016-10-21 | 2019-08-09 | 伦敦国王学院 | Dental treatment |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011062147A1 (en) | 2011-05-26 |
| JP5808053B2 (en) | 2015-11-10 |
| CN102686720B (en) | 2013-12-04 |
| EP2502985A4 (en) | 2013-04-24 |
| US20120231091A1 (en) | 2012-09-13 |
| JPWO2011062147A1 (en) | 2013-04-04 |
| CN102686720A (en) | 2012-09-19 |
| US8993000B2 (en) | 2015-03-31 |
| EP2502985B1 (en) | 2015-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8993000B2 (en) | Method for inducing differentiation of dental pulp cells into odontoblasts | |
| Soudi et al. | Role and application of stem cells in dental regeneration: A comprehensive overview | |
| Zheng et al. | Stem cell-based bone and dental regeneration: a view of microenvironmental modulation | |
| US9682107B2 (en) | Postnatal stem cells and uses thereof | |
| Giannopoulou et al. | Effects of nicotine on periodontal ligament fibroblasts in vitro | |
| Dan et al. | The influence of cellular source on periodontal regeneration using calcium phosphate coated polycaprolactone scaffold supported cell sheets | |
| Sun et al. | Biological approaches toward dental pulp regeneration by tissue engineering | |
| CN108239142B (en) | Novel Peptides | |
| JP2025540802A (en) | Novel peptides | |
| Wang et al. | Research progress in cell therapy for oral diseases: focus on cell sources and strategies to optimize cell function | |
| Babaki et al. | Odontoblast-like cytodifferentiation of dental stem cells: a review | |
| Li et al. | Research progress of odontogenic extracellular vesicles in regeneration of dental pulp | |
| Tziafas | Dentinogenic potential of the dental pulp: facts and hypotheses | |
| WO2010021162A1 (en) | Cell preparation for bone tissue regeneration | |
| EP1990056A1 (en) | Tooth root formation promoter and method for promotion of tooth root formation | |
| EP4656174A1 (en) | Injectable compositions comprising enamel matrix derivative (emd) proteins and human soft tissue cells | |
| CA2809164C (en) | Postnatal stem cells and uses thereof | |
| EP4656213A1 (en) | Injectable compositions of emd fraction b | |
| Nor et al. | Stem Cells from Human Exfoliated Deciduous Teeth in Tissue Regeneration | |
| JPWO2019074046A1 (en) | Method for producing a cell population enriched with periodontal ligament stem cells | |
| Seitz | 2-D and 3-D adipocyte cell culture-promising tools for basic research and approaches towards clinical therapies | |
| HK40112580A (en) | Peptides, compositions comprising the same and use thereof | |
| KR20250104720A (en) | Novel peptide | |
| HK1254601B (en) | Novel peptide | |
| HK40034207B (en) | Peptides, compositions comprising the same and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20120614 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: KUROSAKA, HIROSHI NATIONAL UNIVERSITY CORPORATION Inventor name: KAWANABE, NORIAKI Inventor name: YAMASHIRO, TAKASHI |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: KUROSAKA, HIROSHI Inventor name: KAWANABE, NORIAKI Inventor name: YAMASHIRO, TAKASHI |
|
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20130326 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 36/258 20060101ALI20130320BHEP Ipc: A61K 45/00 20060101ALI20130320BHEP Ipc: A61P 1/02 20060101ALI20130320BHEP Ipc: A61K 38/17 20060101ALI20130320BHEP Ipc: C12N 5/077 20100101ALI20130320BHEP Ipc: A61P 43/00 20060101ALI20130320BHEP Ipc: A61K 33/40 20060101ALI20130320BHEP Ipc: A61K 33/14 20060101ALI20130320BHEP Ipc: C12N 5/07 20100101AFI20130320BHEP Ipc: A61K 38/16 20060101ALI20130320BHEP |
|
| 17Q | First examination report despatched |
Effective date: 20140424 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| INTG | Intention to grant announced |
Effective date: 20141203 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 724455 Country of ref document: AT Kind code of ref document: T Effective date: 20150515 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602010024383 Country of ref document: DE Effective date: 20150611 |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20150429 |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 724455 Country of ref document: AT Kind code of ref document: T Effective date: 20150429 |
|
| REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150429 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150831 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150429 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150429 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150429 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150729 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150429 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 6 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150429 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150429 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150730 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150829 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150429 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150429 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150429 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602010024383 Country of ref document: DE |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150429 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150429 Ref country code: RO Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150429 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150429 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| 26N | No opposition filed |
Effective date: 20160201 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150429 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150429 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151116 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150429 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20151130 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20151130 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150429 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20151116 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 7 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150429 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150429 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20101116 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150429 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150429 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150429 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 8 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150429 Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150429 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150429 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20191121 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20191120 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20191120 Year of fee payment: 10 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602010024383 Country of ref document: DE |
|
| GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20201116 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201130 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201116 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210601 |
